Trial Profile
Safety and efficacy of Peginterferon alfa 2a (pegasys) given once weekly and once monthly in patients with essential thrombocythaemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2014
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Essential thrombocythaemia
- Focus Adverse reactions; Therapeutic Use
- 17 Sep 2014 New trial record
- 10 Dec 2013 Primary endpoint: Haematological response to Pegasys at 12 months was met